11 Apr
2018
02:00 E.S.T.

Cellectis to Present Data at the 2018 AACR Annual Meeting

Read more

10 Apr
2018
16:10 E.S.T.

Cellectis Announces Closing of Follow-On Offering

Read more

09 Apr
2018
08:30 E.S.T.

Allogene Therapeutics Completes Agreement for Pfizer’s Allogeneic CAR T Immuno-­oncology Portfolio

Read more

04 Apr
2018
20:30 E.S.T.

Cellectis Announces Pricing of Follow-On Offering

Read more

03 Apr
2018
16:51 E.S.T.

Cellectis Announces Launch of Follow-On Offering

Read more

03 Apr
2018
08:10 E.S.T.

Cellectis and Allogene Therapeutics Intend to Continue Strategic Cancer Immunotherapy Collaboration to Accelerate Development and Commercialization of Allogeneic Off-the-Shelf CAR T Therapies

Read more

13 Mar
2018
16:30 E.S.T.

Dr. Mathieu Simon to Retire as Cellectis’ Chief Operating Officer; Elsy Boglioli Named as Successor

Read more

12 Mar
2018
16:52 E.S.T.

Cellectis Reports 4th Quarter and Full Year 2017 Financial Results

Read more

08 Mar
2018
16:30 E.S.T.

Servier and Pfizer Announce Results of UCART19 First-in-Human Trials to Be Presented at the 44th EBMT (European Society for Blood and Marrow Transplantation) Annual Meeting

Read more

13 Feb
2018
00:00 E.S.T.

Two Issued U.S. Patents Granted to Cellectis for CRISPR Use in T-Cells

Read more